From Startup to Nasdaq: Shaun Bagai on Clinical Evidence, Physician Trust, and Scaling RenovoRx

Описание: After stepping away from the traditional path to medical school, Shaun Bagai pursued a different way to impact patient care: building technologies that change how treatments reach patients. That path eventually led him to RenovoRx, where the challenge wasn’t just developing innovative oncology technology; it was proving its value in a clinical environment that demands rigorous evidence.

In this episode of Pharma Sessions, host Jonathan Kaskey sits down with Shaun Bagai, CEO of RenovoRx, to unpack the 11-year journey of scaling a two-person startup into a Nasdaq-listed company advancing Phase 3 trials. Bagai shares why physician feedback forced a complete commercial pivot, how prioritizing clinical evidence over quick exits shaped the company’s trajectory, and why real-world relationships with clinicians remain one of the most powerful advantages in healthcare commercialization.

What You’ll Learn:
Why saying "no" to your board's quick-flip strategy was the inflection point
How to identify when physician feedback should reshape your commercial roadmap
The irreplaceable competitive advantage of face-to-face field presence
How to build a lean, efficient salesforce without sacrificing market intelligence
The leadership paradox of staying hands-on in a small organization
Why turning down med school and stable Medtronic roles paid off, and how to evaluate your own "leap" decision

Shaun Bagai is CEO of Renovo RX, a NASDAQ-listed oncology company pioneering transarterial micro perfusion, a breakthrough drug delivery platform that localizes chemotherapy directly to tumors. With over two decades of experience spanning clinical research, regulatory affairs, and commercial strategy across Medtronic, Heartflow, and multiple high-impact startups, Bagot has built a reputation for translating early-stage innovation into scalable, evidence-based solutions.

YouTube Chapters:
[00:00] Intro
[02:29] From Med School to Building Companies That Impact Patients
[08:40] Why Shaun Left Stable Medtronic Roles for Two-Person Startups
[14:33] The Clinical Trial Turning Point: When Physicians Demand Evidence
[17:12] Building Consensus When Your Board Says "Over My Dead Body"
[18:26] Hyperlocalized Drug Delivery: Targeting Tumors Without Systemic Toxicity
[20:56] Why Precision Drug Delivery Is the Future of Cancer Treatment
[22:31] Face-to-Face Relationships as Your Unfair Competitive Advantage
[24:33] The "Invisible Weight" of CEO Communication in Small Teams
[26:41] The AI World Still Can't Replicate the Elevator Conversation
[28:46] Advice for Taking the Leap: Mentorship, Gut Instinct, and Alignment
[30:38] Key Takeaways: Evidence Over Hype, Relationships Over Efficiency

Episode Resources:
RenovoRx Website: https://renovorx.com/
Shaun Bagai on LinkedIn:   / shaun-r-bagai  
Jonathan Kaskey on LinkedIn:   / jonkaskey  
XSUNT Corporation Website: http://www.xsunt.com/